Prostate Cancer

William G. Nelson, Emmanuel S. Antonarakis, H. Ballentine Carter, Angelo M. De Marzo, Theodore L. DeWeese

Research output: Chapter in Book/Report/Conference proceedingChapter

4 Scopus citations

Abstract

Prostate cancer is one of the most common health threats for men in the developed world. With the advent of prostate cancer screening using serum prostate-specific antigen (PSA) tests, prostate cancer mortality has declined at the expense of substantial disease overtreatment. Active surveillance of low-risk prostate cancer may obviate the need for immediate treatment for many men. Surgery and radiation therapy remain mainstay approaches to localized prostate cancer; systemic treatments targeting androgen signaling are used for more advanced disease. Taxane chemotherapy and poly (ADP-ribose) polymerase (PARP) inhibitors are emerging as treatment options for castration-resistant prostate cancer (CRPC).

Original languageEnglish (US)
Title of host publicationAbeloff’s Clinical Oncology
PublisherElsevier
Pages1401-1432.e7
ISBN (Electronic)9780323476744
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2017 Elsevier Inc.

Keywords

  • Active surveillance
  • Androgen deprivation therapy
  • Antiandrogen
  • Intensity-modulated radiation therapy
  • Poly (ADP-ribose) polymerase (PARP) inhibitors
  • Proliferative inflammatory atrophy
  • Prostate cancer
  • Prostate-specific antigen
  • Radical prostatectomy
  • Taxane chemotherapy

Fingerprint

Dive into the research topics of 'Prostate Cancer'. Together they form a unique fingerprint.

Cite this